In July 2018, Petrovax Pharm received Marketing Authorization No.
Grippol® Quadrivalent will be manufactured in Russia
The key benefit of the Russian quadrivalent vaccine is a high efficacy with a low reactogenicity.
Only six countries manufacture quadrivalent vaccines on their own, including Australia, the USA, Canada, New Zealand, Germany, and France. Russia is the 7th country that has independent vaccine production capacities.
For more information follow the link http://petrovax.com/press_centre/news/2018/1344/